Skip to content
OpenCapital
Get started

TherapeuticsMD TXMD Q4 2025 Annual earnings

Reported March 30, 2026 · Before market open

Revenue$893.0KMiss by $18.9MDiluted EPS-$0.05Beat by $6.07
Revenue estimate$19.8M
EPS estimate-$6.13

Next report

Aug 17, 2026 (in a month)
Revenue estimate$22.1M
EPS estimate-$5.50

Versus estimates

Revenue

Q1 2026$724.0KMiss by $19.0M
Q4 2025$893.0KMiss by $18.9M
Q3 2025$784.0KQ2 2025$952.0KQ1 2025$393.0KQ4 2024$667.0KMiss by $1.6M

Diluted EPS

Q1 2026$0.01Beat by $6.14
Q4 2025-$0.05Beat by $6.07
Q3 2025$0.01Q2 2025$0.05Q1 2025-$0.06Q4 2024$0.02Miss by $0.02

Ask the moment TherapeuticsMD reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did TherapeuticsMD report Q4 2025 earnings?
TherapeuticsMD (TXMD) reported Q4 2025 earnings on March 30, 2026 before market open.
What were TherapeuticsMD's Q4 2025 revenue and EPS?
TherapeuticsMD reported revenue of $893.0K and diluted EPS of $-0.05 for Q4 2025.
Did TherapeuticsMD beat estimates in Q4 2025?
Revenue missed the consensus estimate of $19.8M by $18.9M. EPS beat the consensus estimate of $-6.13 by $6.07.
How did TherapeuticsMD's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 33.9% from $667.0K a year earlier.
Where can I find TherapeuticsMD's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001213900-26-036519) and the 10-K periodic report (0001213900-26-036515) directly on SEC EDGAR. The filing index links above go to sec.gov.